NMN supplement effects: what is supported by evidence and what the EU rules say

8. Juni 2026 ca. 25 Minuten

What to expect in this article

1. What NMN is and what NAD+ has to do with it
2. What the law says in Germany and the EU
3. The 2026 EFSA opinion and what follows from it
4. Why there are no permitted health claims for NMN
5. The NAD+ narrative in three steps, examined individually
6. How a substance becomes marketable in the EU
7. Why mouse data cannot be extrapolated to humans
8. What human studies actually measured
9. Three NAD+ precursors and their very different legal status
10. What a DNA test can and cannot contribute to this question
11. How to recognize an impermissible advertising claim
12. Limitations: what this article does not answer
13. What matters about this topic
14. Frequently asked questions
15. Sources

What NMN is and what NAD+ has to do with it

NMN is short for nicotinamide mononucleotide, a small molecule involved in the metabolism of vitamin B3. It is not an invention of the dietary supplement industry, but an intermediate product known for decades that occurs in every human cell and is also found in trace amounts in foods.

The molecule attracted interest because of its role as a precursor. A precursor is a substance the body uses to make another substance. In NMN’s case, that other substance is NAD+, short for nicotinamide adenine dinucleotide.

What is a coenzyme, and why is NAD+ mentioned so often?

A coenzyme is a helper molecule that an enzyme needs in order to do its job. NAD+ is one such helper, and an especially versatile one: it transfers electrons in the respiratory chain and also serves as a building block for a range of enzymes involved in repair and regulatory processes.

This dual role explains the attention. A molecule involved in both energy metabolism and cell regulation can be linked to almost any health topic. But that is also the weakness of the narrative: a substance involved in everything is rarely the one lever that everything depends on.

In our metabolism, NAD+ works more like a library card in a workshop than a tool. It is constantly checked out, used, returned, and checked out again. Whether having more cards in circulation leads to more things being built depends on whether the cards were actually the bottleneck.

Where NMN fits into vitamin B3 metabolism

The body has several ways of producing NAD+. It can build it from the amino acid tryptophan, obtain it from nicotinic acid and nicotinamide, or recover it from already-used material through so-called salvage pathways. NMN sits on one of these pathways, immediately before the final step.

This proximity to the end product is the industry’s main argument: a short path, with few conversion steps. But it is not evidence of a benefit; it is a description of biochemistry. Several levels of evidence separate a plausible reaction pathway from a proven effect in humans, and this article examines them one by one.

What the law says in Germany and the EU

Before discussing effects, there is a preliminary question: Can the substance even be sold as a food here? For NMN, the answer as of August 28, 2026, is no, and this answer predates and is more firmly established than any body of research.

The key legislation is the European regulation on novel foods. The German Federal Office of Consumer Protection and Food Safety explains the term as follows: A novel food is any food that was not used for human consumption to a significant degree in the European Union before May 15, 1997. According to the BVL, such foods must undergo a safety assessment before they can be placed on the market.

In its information on NAD and NMN, the consumer advice center first discusses NAD+ itself and then compares it with NMN. The following quote, with the word “by contrast,” refers to this comparison.

Why the substance is still being offered

The fact that a substance is available to buy online says nothing about whether it can legally be marketed in the EU. A substantial share of the products on offer comes from countries with different regulations and reaches buyers via direct shipping. Food inspectors intervene only when they encounter a specific case.

For you as a reader, this has a practical consequence that has little to do with biochemistry. For a product without European authorization, there are no officially verified details about its purity and content. What is stated on the package is then just the manufacturer’s claim.

The 2026 EFSA opinion and what follows from it

Something has shifted on this issue in 2026, and this development is currently often misrepresented. That is why it is covered here in detail.

The European Food Safety Authority’s Panel on Nutrition, Novel Foods and Food Allergens adopted an opinion on beta-nicotinamide mononucleotide. It was adopted on March 4, 2026, and published on May 11, 2026, in the EFSA Journal. The substance was assessed as an ingredient in food supplements and as a source of nicotinamide, a form of the vitamin niacin.

The Panel concluded that the substance is safe for the adult population under the proposed conditions of use, excluding pregnant and breastfeeding women, and that it is a bioavailable source of nicotinamide. The proposed and assessed maximum amount was 300 milligrams per day. This figure is a basis for assessment from an authorization application, not a recommendation for individuals.

Three things this opinion explicitly does not say

First, it says nothing about efficacy. The opinion itself states that the assessment relates exclusively to the risks that could be associated with consumption under the proposed conditions, and that it is not an assessment of efficacy with regard to any claimed benefit. It is hard to state the difference between safety and effectiveness more clearly.

Second, an EFSA opinion is not an authorization. EFSA assesses; the European Commission decides together with the Member States. A substance can only be marketed once it has been added to the Union list of authorized novel foods. According to the list as accessed on August 28, 2026, NMN is not on it.

Third, the application does not concern the longevity narrative, but vitamin intake. NMN was assessed as a source of nicotinamide. The context in which the substance might one day be permitted is therefore niacin nutrition, not holding back aging.

Why there is no permitted efficacy claim for NMN

Even if a substance can legally be marketed, it cannot be advertised freely. Health claims about foods are specifically regulated in the EU and are permitted only if they have first been assessed and added to a list. That list includes several claims for niacin, such as its contribution to normal energy metabolism, set out in Regulation (EU) No 432/2012.

There is nothing for NMN. In its statement dated January 16, 2026, the consumer advice center notes that there are currently no authorized health claims whatsoever, and also states that scientific evidence is lacking to show that NMN as a dietary supplement for humans is a fountain of youth, makes people healthier and more vital, or prolongs life.

This has a stark consequence for any text on this topic. There is no watered-down wording that is permissible. A sentence such as “may support energy metabolism” is not a cautious version of an efficacy claim, but an efficacy claim. Using the subjunctive does not change its legal classification.

The scale of the evidence

Sources: European Commission, Union list of novel foods and Regulation (EU) No 432/2012, accessed 2026 · Igarashi and colleagues, npj Aging, 2022

The NAD+ story in three links, examined individually

Almost every text about NMN tells the same chain. It goes like this: NMN raises NAD+ levels, NAD+ levels decline with age, so NMN counteracts aging. The chain sounds convincing because each link seems plausible on its own. It is hardly ever examined, because its three links are supported by very different levels of evidence.

First link: Does NMN raise NAD+ levels?

For the blood marker, the answer is yes. In a double-blind, placebo-controlled study of healthy older men, blood levels of NAD+ and its breakdown products increased measurably. Igarashi and colleagues reported this in npj Aging (2022), using 250 milligrams daily for twelve weeks and evaluating twenty participants.

So the first link holds. But it holds more narrowly than it is usually cited: measurements were taken in blood. That does not answer whether or to what extent levels in muscle, liver, adipose tissue, or brain follow suit. A review by Vinten and colleagues in Nature Metabolism (2025) explicitly notes that published data on NAD+ dynamics in human tissues remain scarce.

Second link: Do NAD+ levels decline with age?

This is where the chain breaks for the first time. A review by Peluso and colleagues in Nutrients (2022) brought together the available measurements across several species and concluded that the evidence for a general age-related decline is very limited and mostly confined to a single tissue or cell type. In humans, the course of NAD+ levels during aging has so far been poorly characterized.

The review by Vinten and colleagues (2025) puts it in similarly cautious terms: an age-related decline in NAD+ levels in humans has been consistently observed in only a limited number of studies. A statement presented as self-evident is therefore an open research question.

Third link: Does this lead to rejuvenation?

The third link does not hold. It would not hold even if the first two did, because an increase in concentration does not establish an outcome unless the outcome itself has been measured. Vinten and colleagues summarize the clinical picture in Nature Metabolism (2025), noting that studies in humans have so far shown limited efficacy.

This gap between marker and outcome is precisely where sound interpretation and advertising diverge. Advertising cites the first link and concludes the third. The evidence for that is missing.

How a substance becomes marketable in the EU

To understand why a positive safety opinion and an authorized product are two different things, you need to know the path a novel food takes through the EU. It has four stages, and their order is mandatory.

The process applied to NMN

The fourth step is the one most often overlooked. Even a substance that is eventually included on the Union list cannot therefore be advertised as having an effect. This has been the case since 2020 for the related precursor nicotinamide riboside chloride: approved as an ingredient, with no approved health claim of its own.

Why mouse data cannot be extrapolated to humans

NMN's reputation comes mainly from animal studies. Over the years, findings on metabolism, endurance, and vascular function have been reported in mouse models, and these findings are presented as proof in promotional copy, usually without naming the animal species.

The review by Vinten and colleagues in Nature Metabolism (2025) states the problem directly: transferring data from rodents is not straightforward. This is not a mere formality; there are concrete reasons.

Four reasons why mice and humans are worlds apart

The first reason is lifespan. A laboratory mouse lives for two to three years. An intervention that works over several months in a mouse corresponds to a period in humans that no study has yet covered.

The second reason is genetic uniformity. Laboratory strains are largely identical and live under controlled conditions. People differ in genetics, diet, exercise, sleep, and pre-existing conditions, and each of these differences can mask a small effect.

The third reason is the dose. In animal studies, amounts are given per kilogram of body weight and cannot be converted linearly to humans, because metabolic rates and excretion differ between species.

The fourth reason is the study design. Many animal studies use deliberately induced deficiency or disease states. An effect that corrects an artificially induced deficiency says little about a healthy person without that deficiency.

What human studies actually measured

There are studies in humans, but they are small and short, and their results are inconsistent. The most frequently cited is the previously mentioned study by Igarashi and colleagues in npj Aging (2022). It is a good example because it shows both what changed and what did not.

Healthy older men were studied. Twenty participants were assessed, ten per group. The study administered 250 milligrams daily for twelve weeks. These details describe a study design and are explicitly not instructions for taking it.

What changed

The concentration of NAD+ and its breakdown products in the blood increased. The analysis also found differences in walking speed and left-hand grip strength. The substance was well tolerated in this study, and no serious adverse events were reported.

What did not change

The list of endpoints showing no difference is longer than the list of those that did. No effect was reported on skeletal muscle mass, there was no meaningful change in body composition, no effect on liver or abdominal fat, and no effect on insulin sensitivity or glucose metabolism.

That is exactly what an honest picture of the evidence looks like. One marker changes, some measures of function change along with it in a very small group, and most of the measured variables remain unchanged. Anyone who draws a promise of longevity from this is not reading the study, but using its title.

A second point also needs to be kept in mind with small groups. With twenty people assessed and a range of endpoints considered at the same time, a single striking result can easily occur by chance. Such a finding becomes robust only when repeated in larger, independent studies.

Three NAD+ precursors and their very different legal statuses

NMN is not the only precursor in the same metabolic pathway. A comparison of the three best-known ones shows that their legal status does not depend on their biochemical similarity, but on whether a procedure has been completed.

The middle column is the most revealing. Nicotinamide riboside chloride has gone through the process and is authorized, yet there is no specific authorized health claim for it. Authorization as an ingredient and permission to advertise are two separate things, and both are lacking for NMN.

What a DNA test can and cannot tell you about this question

Many texts make the transition to the product at this point. Here, it should be stated openly, because in this case it does not hold: a DNA test does not measure NAD+, and it says nothing about the effects of a dietary supplement.

A saliva test reads specific positions in the DNA sequence. It describes predispositions that do not change over a person’s lifetime. NAD+, by contrast, is a metabolic state that shifts over the course of hours and would need to be measured using a blood or tissue sample. These belong to different categories, and no genotype can be translated into an NAD+ level.

What a genetic report can tell you is a different matter. It describes predispositions related to nutrition, exercise, and metabolism, providing a starting point for decisions that do not depend on a single molecule. That is less than longevity marketing promises, and it can be verified. The mybody®x (MYBODY Lab GmbH) test is therefore presented here explicitly not as an answer to the NMN question, but as what it is.

This distinction also applies to our article What Is Epigenetics. That article looks at how gene activity is regulated and what a saliva test can read from it. This article is about a single substance, its legal status, and the state of the research. If you want to know what genetic analyses actually measure, that article is a better fit.

How to recognize an impermissible advertising claim

The most useful skill for this topic isn’t specialist knowledge about NAD+, but an eye for how a claim is constructed. Four questions are enough, and they work for any other longevity claim, too.

The fourth step is the quickest, so it’s worth starting there. It requires no specialist knowledge and debunks most claims in a few seconds.

It is also striking which words regularly appear in texts like these: rejuvenation, cellular aging, molecular reset, fountain of youth. None of these words is a measurement. They replace a description of what was actually studied with an image everyone understands and no one can verify.

Limitations: what this article does not answer

This text provides context; it does not make a recommendation. It says neither that NMN is useless nor that it is useful. It says that neither has been proven at this time and that the substance cannot be marketed here. These are two different statements, and the second is better supported.

The legal situation may change. A safety assessment has been available since May 2026, and a decision by the European Commission is pending. If it approves authorization, that will change whether the substance can be marketed, but nothing about its effects. A claim about its effects would require a separate procedure and data that are not available today.

There is still a gap in the research that this article cannot fill. Large, long-term studies by independent groups, involving people and measuring outcomes that matter in everyday life, are lacking. As long as they are, any claims about benefits remain extrapolations from small groups and short timeframes.

The caveat from Chapter Ten also applies unchanged to mybody®x products. None of the tests in the range measures NAD+, none tests the effects of a supplement, and none answers the question that brought you to this page. Anyone who wants an answer will have to wait for research findings that do not yet exist.

What matters on this topic

It began with the question of NMN’s effects. Based on current knowledge, that question cannot be answered, and that is itself an answer: A substance for which there is not a single authorized health claim in the EU and which is not on the Union list has no effect that could be advertised.

What remains from this article is less a statement about NMN than a tool. The chain linking marker, aging, and rejuvenation comes up again with every new longevity substance, usually with only the molecule’s name changed. Once you’ve broken it down into its links, you recognize it next time by its structure, before you’ve even read the name.

The specific next step, then, is not a purchase but a habit: the next time you encounter a claim about an effect, first check whether there is an authorized health claim for it. It takes a minute and answers more questions than reading any study.

Frequently asked questions

Sources

1. Verbraucherzentrale: NAD and NMN in food supplements? (as of January 16, 2026) – verbraucherzentrale.de
2. Federal Office of Consumer Protection and Food Safety: Novel Foods (accessed 2026) – bvl.bund.de
3. EFSA Panel on Nutrition, Novel Foods and Food Allergens: Safety of beta-nicotinamide mononucleotide (β-NMN) … EFSA Journal, adopted March 4, 2026, published May 11, 2026 – efsa.onlinelibrary.wiley.com
4. European Commission: Union list of authorized novel foods, Commission Implementing Regulation (EU) 2017/2470 (accessed 2026) – food.ec.europa.eu

The statements about the Novel Food status of NMN, the absence of approved health claims and the lack of evidence for claims that it is a fountain of youth are based on [1]. The definition of a novel food, the cutoff date of May 15, 1997, the requirement for authorization before marketing and the role of the Union list come from [2]. The date of adoption, March 4, 2026, the publication date, May 11, 2026, the assessed maximum amount of 300 milligrams per day, its classification as a source of nicotinamide and the explicit exclusion of an efficacy assessment come from [3]. The fact that NMN is not included in the Union list was checked against [4]. The study details on 250 milligrams daily for twelve weeks, twenty participants analyzed and the endpoints that changed and those that did not come from a paper by Igarashi and colleagues in npj Aging (2022); statements about the evidence in humans come from reviews by Peluso and colleagues in Nutrients (2022) and Vinten and colleagues in Nature Metabolism (2025); the authorization of nicotinamide riboside chloride comes from Commission Implementing Regulation (EU) 2020/16 of January 10, 2020. These four references are attributed in the text by authorship or source and year, and are therefore not included in the list. Information on price, genetic variations, report count, sample type and laboratory comes from the mybody®x product page, accessed on 08/27/2026; processing times follow the central guideline for DNA tests. All sources were accessed and checked on 08/28/2026.